

-1-

Title**Method of treating thrombocytopenic purpura and hemolytic uremic syndrome**

5 This application claims priority of Provisional Application Serial No. 60/111,770 filed December 10, 1998.

Field of the Invention

This invention relates to medical science particularly
10 the treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome with protein C.

Background of the Invention

Protein C is a vitamin K dependent serine protease and
15 naturally occurring anticoagulant that plays a role in the regulation of hemostasis by inactivating Factors Va and VIIIa in the coagulation cascade. Human protein C circulates as a 2-chain zymogen, but functions at the endothelial and platelet surface following conversion to
20 activated protein C (aPC) by limited proteolysis with thrombin in complex with the cell surface membrane protein, thrombomodulin.

25 "Express Mail" mailing label number EL041988283US

Date of Deposit Dec 10, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Queen Thomas
Printed Name

Queen Thomas
Signature

In conjunction with other proteins, aPC functions as perhaps the most important down-regulator of blood coagulation resulting in protection against thrombosis. In addition to its anti-coagulation functions, aPC has anti-
5 inflammatory effects through its inhibition of cytokine generation (e.g. TNF and IL-1) and also exerts profibrinolytic properties, such as the inhibition of PAI-1, that facilitate clot lysis. Thus, the protein C enzyme system represents a major physiological mechanism of anti-
10 coagulation, anti-inflammation, and fibrinolysis.

Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are defined as thrombotic microangiopathies characterized by occlusion of arterioles and capillaries by microthrombi, thrombocytopenia, 15 impairment of neurologic function and progressive renal failure. TTP has been defined as a multisystem disease characterized by fever, fluctuating central nervous system abnormalities, renal failure, microangiopathic hemolytic anemia and thrombocytopenia. HUS is characterized by 20 intravascular hemolytic anemia associated with fragmented red cells; thrombocytopenia; and end-organ damage with either (a) histological evidence of a thrombotic microangiopathic process (most commonly in the kidneys), or (b) clinical evidence of such damage in the absence of any 25 other disease or likely cause [Neild, G., Kidney International 53 (Suppl. 64): S-45-S-49, 1998].

Contributing factors to the pathophysiology of TTP/HUS are believed to be endothelial cell damage and primary platelet aggregation [Moake, Seminars in Hematology, 34(2): 30 83-89, 1997]. Endothelial damage leads to release of

unusually large von Willebrand factor (UL vWF) multimers, which in turn leads to platelet aggregation. Fibrin thrombi accumulate on the platelet thrombi as a result of depression of the body's fibrinolytic system. In HUS and TTP elevated 5 levels of plasminogen activator inhibitor (PAI-1) and decreased levels of protein C activity have been found.

TPP has been associated with bacterial infections of the *Bartonella* sp., as well as with HIV and visceral Kaposi's sarcoma [Avery et al, American Journal of 10 Hematology, 58:148-149, 1998]. TTP has also been associated with the use of numerous drugs, for example, ticlopidine, FK506, high-dose corticosteroids, tamoxiphen, or cyclosporin A [Gordon et al., Seminars in Hematology, 34(2): 140-147, 1997].

15 HUS has been associated with numerous bacterial infections, for example, *E. coli* O157:H7 strain, *Shigella*, *Pneumococci*, hemolytic *Streptococci*, or *Yersinia*. HUS has also been associated with viral infections, for example, HIV, Coxsackie, or adenovirus. In addition, HUS has been 20 associated with the use of numerous drugs similar to those listed above for TPP [Gordon et al., 1997]. Both TTP and HUS have been associated with complications during pregnancy [Egerman et al., Am J Obstet Gynecol, 175: 950-956, 1996].

25 The clinical findings of thrombotic microangiopathies include microangiopathic hemolytic anemia (MAHA), acute renal failure, thrombocytopenia and in TTP, acute neurologic changes. Left untreated, TTP and HUS have a poor prognosis with mortality rates reaching 90%. Surviving patients often develop end-stage renal disease. The only treatment method 30 with a favorable outcome has been plasma exchange [PE] with

fresh frozen plasma [Hollenbeck et al., Nephrol Dial Transplant 13: 76-81, 1998]. However, deaths still occur and many patients suffer long term complications even if treated with PE. Therefore, a need exists for a more 5 effective treatment of TTP and/or HUS.

The present invention is the first to describe the treatment of TTP and/or HUS with protein C. Protein C, with its anticoagulant and profibrinolytic activities along with its ability to inactivate PAI-1, is useful for the treatment 10 of the occlusion of arterioles and capillaries by microthrombi that occur in patients with TTP and HUS.

Summary of the Invention

The present invention provides a method of treating a 15 patient suffering from thrombotic thrombocytopenic purpura (TTP) which comprises, administering to said patient a pharmaceutically effective amount of protein C.

In another embodiment, the present invention provides a method of treating a patient suffering from hemolytic uremic 20 syndrome (HUS) which comprises, administering to said patient a pharmaceutically effective amount of protein C.

In another embodiment, the present invention provides a method of treating thrombotic thrombocytopenic purpura (TTP) in a patient in need thereof, which comprises administering 25 to said patient a pharmaceutically effective amount of activated protein C such that an activated protein C plasma level of about 2 ng/ml to about 300 ng/ml is achieved.

In still another embodiment, the present invention provides a method of treating hemolytic uremic syndrome 30 (HUS) in a patient in need thereof, which comprises

administering to said patient a pharmaceutically effective amount of activated protein C such that an activated protein C plasma level of about 2 ng/ml to about 300 ng/ml is achieved.

5

Detailed Description of the Invention

For purposes of the present invention, as disclosed and claimed herein, the following terms are as defined below.

Protein C refers to a vitamin K dependent serine
10 protease with anticoagulant, anti-inflammatory, and profibrinolytic properties which includes, but is not limited to, plasma derived and recombinant produced protein C. Protein C includes and is preferably human protein C although protein C may also include other species or
15 derivatives having protein C proteolytic, amidolytic, esterolytic, and biological (anticoagulant, pro-fibrinolytic, and anti-inflammatory) activities. Examples of protein C derivatives are described by Gerlitz, et al., U.S. Patent No. 5,453,373, and Foster, et al., U.S. Patent
20 No. 5,516,650, the entire teachings of which are hereby included by reference.

Zymogen - an enzymatically inactive precursor of a proteolytic enzyme. Protein C zymogen, as used herein, refers to secreted, inactive forms, whether one chain or two
25 chains, of protein C.

Activated protein C or aPC refers to protein C zymogen which has been converted by limited proteolysis to its activated form. aPC includes and is preferably human protein C although aPC may also include other species or
30 derivatives having protein C proteolytic, amidolytic,

esterolytic, and biological (anticoagulant or pro-fibrinolytic) activities. Examples of protein C derivatives are noted above in the description of protein C.

HPC - human protein C zymogen.

5 r-hPC - recombinant human protein C zymogen.

r-aPC - recombinant human activated protein C produced by activating r-hPC *in vitro* or by direct secretion of the activated form of protein C from prokaryotic cells, eukaryotic cells, and transgenic animals or plants, 10 including, for example, secretion from human kidney 293 cells as a zymogen then purified and activated by techniques well known to the skilled artisan and demonstrated in Yan, U.S. Patent No. 4,981,952, and Cottingham, WO97/20043, the entire teachings of which are herein incorporated by 15 reference.

Plasma derived activated protein C - activated protein C produced by activating plasma HPC as described in Eibl, U.S. Patent No. 5,478,558, the entire teaching of which is herein incorporated by reference.

20 Continuous infusion - continuing substantially uninterrupted the introduction of a solution into a vein for a specified period of time.

Bolus injection - the injection of a drug in a defined quantity (called a bolus) over a period of time up to about 25 120 minutes.

Suitable for administration - a lyophilized formulation or solution that is appropriate to be given as a therapeutic agent.

Unit dosage form - refers to physically discrete units 30 suitable as unitary dosages for human subjects, each unit

containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

Pharmaceutically effective amount - represents an
5 amount of a compound of the invention that is capable of inhibiting sepsis in humans. The particular dose of the compound administered according to this invention will, of course, be determined by the attending physician evaluating the particular circumstances surrounding the case.

10

The present invention provides for the treatment of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) with protein C. TTP has been defined as a multisystem disease characterized by fever, fluctuating
15 central nervous system abnormalities, renal failure, microangiopathic hemolytic anemia and thrombocytopenia. HUS is characterized by intravascular hemolytic anemia associated with fragmented red cells; thrombocytopenia; and end-organ damage with either (a) histological evidence of a
20 thrombotic microangiopathic process (most commonly in the kidneys), or (b) clinical evidence of such damage in the absence of any other disease or likely cause. Protein C, with its anticoagulant and profibrinolytic activities along with its ability to inactivate PAI-1, is useful for the
25 treatment of the occlusion of arterioles and capillaries by microthrombi that occur in patients with TTP and HUS.

The protein C administered according to this invention may be generated and/or isolated by any means known in the art or as described in U.S. Patent No. 4,981,952, and U.S.
30 Patent No. 5,550,036, herein incorporated by reference. For

example, the invention provides a method for producing and secreting full-length, soluble protein C, or biologically active polypeptide variants of protein C from a cell which comprises (a) constructing a vector comprising DNA encoding protein C; (b) transfecting the cell with the vector; and (c) culturing the cell so transfected in culture medium under conditions such that full length soluble protein C or biologically active polypeptide variants of protein C, is secreted. Further, the cell is a eukaryotic cell, e.g. 5 mammalian cell such as Syrian hamster AV12 cell, human 10 embryonic 293 cell, or Baby Hamster Kidney cell.

The protein C used in the treatment of TTP/HUS can be formulated according to known methods to prepare pharmaceutically useful compositions. For example, a 15 desired formulation would be one that is a stable lyophilized product of high purity comprising a bulking agent such as sucrose, a salt such as sodium chloride, a buffer such as sodium citrate and protein C or aPC.

The protein C will be administered parenterally to 20 ensure its delivery into the bloodstream in an effective form by injecting the appropriate dose as continuous infusion for about 1 hour to about 240 hours.

Those skilled in the art can readily optimize pharmaceutically effective dosages and administration 25 regimens for therapeutic compositions comprising protein C, as determined by good medical practice and the clinical condition of the individual patient. Generally, the amount of protein C administered will be from about 5.0 μ g/kg/hr to about 250 μ g/kg/hr. Preferably, the protein C used in the 30 treatment of TTP/HUS is activated protein C. The amount of

aPC administered will be from about 1.0 $\mu\text{g}/\text{kg}/\text{hr}$ to about 96 $\mu\text{g}/\text{kg}/\text{hr}$. More preferably the amount of aPC administered will be about 1.0 $\mu\text{g}/\text{kg}/\text{hr}$ to about 50 $\mu\text{g}/\text{kg}/\text{hr}$. While more preferably the amount of aPC administered will be about 1.0

5 $\mu\text{g}/\text{kg}/\text{hr}$ to about 35 $\mu\text{g}/\text{kg}/\text{hr}$. Even more preferably the amount of aPC administered will be about 5.0 $\mu\text{g}/\text{kg}/\text{hr}$ to about 30 $\mu\text{g}/\text{kg}/\text{hr}$. Yet even more preferably the amount of aPC administered will be about 15 $\mu\text{g}/\text{kg}/\text{hr}$ to 30 $\mu\text{g}/\text{kg}/\text{hr}$. Still even more preferably the amount of aPC administered

10 will be about 20 $\mu\text{g}/\text{kg}/\text{hr}$ to 30 $\mu\text{g}/\text{kg}/\text{hr}$. The most preferable amount of aPC administered will be about 24 $\mu\text{g}/\text{kg}/\text{hr}$. The appropriate dose of aPC administered will result in a reduction of the occlusions of arterioles and capillaries by microthrombi that occur in patients with TTP

15 and HUS.

The plasma ranges obtained from the amount of aPC administered will be about 2 ng/ml to about 300 ng/ml. The preferred plasma ranges are from about 2 ng/ml to 200 ng/ml. Most preferably, plasma ranges are from about 30 ng/ml to

20 about 150 ng/ml and still more preferably about 100 ng/ml.

Alternatively, the aPC will be administered by injecting one third of the appropriate dose per hour as a bolus injection followed by the remaining two thirds of the hourly dose as continuous infusion for one hour followed by

25 continuous infusion of the appropriate dose for twenty-three hours which results in the appropriate dose administered over 24 hours. In addition, the bolus injection will be administered via an intravenous bag drip pump or syringe pump at about 2 times the normal rate for about 10 to 20

30 minutes followed by about 1.5 times the normal rate for

about 40 to 50 minutes. The normal rate i.e. that rate which has been determined to administer the appropriate dose level of the therapeutic agent per time period, is then continued for up to 240 hours.

5 The use of protein C in the treatment of TTP/HUS as presented in the present invention will provide a needed therapy for potentially serious and debilitating disorders. The use of protein C is efficacious and avoids the complications such as toxicity and general side effects of 10 the currently available therapy of plasma exchange [PE] with fresh frozen plasma or other currently available anti-coagulant agents.

15 The following examples are provided merely to further illustrate the present invention. The scope of the invention shall not be construed as merely consisting of the following examples.

Preparation 1

Preparation of Human Protein C

20 Recombinant human protein C (r-hPC) was produced in Human Kidney 293 cells by techniques well known to the skilled artisan such as those set forth in Yan, U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference. The gene encoding human protein C is disclosed and claimed in Bang, et al., U.S. Patent No. 4,775,624, the entire teaching of which is incorporated herein by reference. The plasmid used to express human protein C in 293 cells was plasmid pLPC which is disclosed 25 in Bang, et al., U.S. Patent No. 4,992,373, the entire 30

teaching of which is incorporated herein by reference. The construction of plasmid pLPC is also described in European Patent Publication No. 0 445 939, and in Grinnell, et al., 1987, Bio/Technology 5:1189-1192, the teachings of which are 5 also incorporated herein by reference. Briefly, the plasmid was transfected into 293 cells, then stable transformants were identified, subcultured and grown in serum-free media. After fermentation, cell-free medium was obtained by microfiltration.

10 The human protein C was separated from the culture fluid by an adaptation of the techniques of Yan, U.S. Patent No. 4,981,952. The clarified medium was made 4 mM in EDTA before it was absorbed to an anion exchange resin (Fast-Flow Q, Pharmacia). After washing with 4 column volumes of 20 mM 15 Tris, 200 mM NaCl, pH 7.4 and 2 column volumes of 20 mM Tris, 150 mM NaCl, pH 7.4, the bound recombinant human protein C zymogen was eluted with 20 mM Tris, 150 mM NaCl, 10 mM CaCl₂, pH 7.4. The eluted protein was greater than 95% pure after elution as judged by SDS-polyacrylamide gel 20 electrophoresis.

Further purification of the protein was accomplished by making the protein 3 M in NaCl followed by adsorption to a hydrophobic interaction resin (Toyopearl Phenyl 650 M, TosoHaas) equilibrated in 20 mM Tris, 3 M NaCl, 10 mM CaCl₂, 25 pH 7.4. After washing with 2 column volumes of equilibration buffer without CaCl₂, the recombinant human protein C was eluted with 20 mM Tris, pH 7.4.

The eluted protein was prepared for activation by removal of residual calcium. The recombinant human protein 30 C was passed over a metal affinity column (Chelex-100, Bio-

Rad) to remove calcium and again bound to an anion exchanger (Fast Flow Q, Pharmacia). Both of these columns were arranged in series and equilibrated in 20 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 7.4. Following loading of the protein, 5 the Chelex-100 column was washed with one column volume of the same buffer before disconnecting it from the series. The anion exchange column was washed with 3 column volumes of equilibration buffer before eluting the protein with 0.4 M NaCl, 20 mM Tris-acetate, pH 6.5. Protein concentrations 10 of recombinant human protein C and recombinant activated protein C solutions were measured by UV 280 nm extinction $E_{0.1\%}=1.81$ or 1.85, respectively.

Preparation 2

15 Activation of Recombinant Human Protein C

Bovine thrombin was coupled to Activated CH-Sepharose 4B (Pharmacia) in the presence of 50 mM HEPES, pH 7.5 at 4°C. The coupling reaction was done on resin already packed into a column using approximately 5000 units thrombin/mL 20 resin. The thrombin solution was circulated through the column for approximately 3 hours before adding 2-amino-ethanol (MEA) to a concentration of 0.6 mL/L of circulating solution. The MEA-containing solution was circulated for an additional 10-12 hours to assure complete blockage of the 25 unreacted amines on the resin. Following blocking, the thrombin-coupled resin was washed with 10 column volumes of 1 M NaCl, 20 mM Tris, pH 6.5 to remove all non-specifically bound protein, and was used in activation reactions after equilibrating in activation buffer.

Purified r-hPC was made 5 mM in EDTA (to chelate any residual calcium) and diluted to a concentration of 2 mg/mL with 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5. This material was passed through a thrombin column equilibrated 5 at 37°C with 50 mM NaCl and either 20 mM Tris pH 7.4 or 20 mM Tris-acetate pH 6.5. The flow rate was adjusted to allow for approximately 20 min. of contact time between the r-hPC and thrombin resin. The effluent was collected and immediately assayed for amidolytic activity. If the 10 material did not have a specific activity (amidolytic) comparable to an established standard of protein C, it was recycled over the thrombin column to activate the r-hPC to completion. This was followed by 1:1 dilution of the material with 20 mM buffer as above, with a pH of either 7.4 15 or 6.5 to keep the protein C at lower concentrations while it awaited the next processing step.

Removal of leached thrombin from the protein C material was accomplished by binding the protein C to an anion exchange resin (Fast Flow Q, Pharmacia) equilibrated in 20 activation buffer (either 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5) with 150 mM NaCl. Thrombin does not interact with the anion exchange resin under these conditions, but passes through the column into the sample application effluent. Once the protein C is loaded onto the 25 column, a 2-6 column volume wash with 20 mM equilibration buffer is done before eluting the bound protein C with a step elution using 0.4 M NaCl in either 5 mM Tris-acetate, pH 6.5 or 20 mM Tris, pH 7.4. Higher volume washes of the column facilitated more complete removal of the 30 dodecapeptide. The material eluted from this column was

stored either in a frozen solution (-20°C) or as a lyophilized powder.

The anticoagulant activity of activated protein C was determined by measuring the prolongation of the clotting time in the activated partial thromboplastin time (APTT) clotting assay. A standard curve was prepared in dilution buffer (1 mg/mL radioimmunoassay grade bovine serum albumin [BSA], 20 mM Tris, pH 7.4, 150 mM NaCl, 0.02% NaN₃) ranging in protein C concentration from 125-1000 ng/mL, while samples were prepared at several dilutions in this concentration range. To each sample cuvette, 50 μL of cold horse plasma and 50 μL of reconstituted activated partial thromboplastin time reagent (APTT Reagent, Sigma) were added and incubated at 37°C for 5 min. After incubation, 50 μL of the appropriate samples or standards were added to each cuvette. Dilution buffer was used in place of sample or standard to determine basal clotting time. The timer of the fibrometer (CoA Screener Hemostasis Analyzer, American Labor) was started immediately after the addition of 50 μL 37°C 30 mM CaCl₂ to each sample or standard. Activated protein C concentration in samples are calculated from the linear regression equation of the standard curve. Clotting times reported here are the average of a minimum of three replicates, including standard curve samples.

The above descriptions enable one with appropriate skill in the art to prepare protein C for utilization in the treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Preparation 3Formulation of Activated Protein C

A stable lyophilized formulation of activated protein C was prepared by a process which comprises lyophilizing a 5 solution comprising about 2.5 mg/mL activated protein C, about 15 mg/mL sucrose, about 20 mg/mL NaCl, and a sodium citrate buffer having a pH greater than 5.5 but less than 6.5. Additionally, the stable lyophilized formulation of activated protein C comprises lyophilizing a solution 10 comprising about 5 mg/mL activated protein C, about 30 mg/mL sucrose, about 38 mg/mL NaCl, and a citrate buffer having a pH greater than 5.5 but less than 6.5.

The ratio of protein C:salt:bulking agent (w:w:w) is an important factor in a formulation suitable for the freeze 15 drying process. The ratio varies depending on the concentration of protein C, salt selection and concentration and bulking agent selection and concentration.

Particularly, a ratio of about 1 part activated protein C to about 7.6 parts salt to about 6 parts bulking agent is 20 preferred.

A unit dosage formulation of activated protein C suitable for administration by continuous infusion was prepared by mixing activated protein C, NaCl, sucrose, and sodium citrate buffer. After mixing, 4 mL of the solution 25 was transferred to a unit dosage receptacle and lyophilized. The unit dosage receptacle containing about 5 mg to about 20 mg of activated protein C, suitable for administering a dosage of about 0.01 mg/kg/hr to about 0.05 mg/kg/hr to patients in need thereof, was sealed and stored until use.

Example 1

A Double Blind Placebo-Controlled Randomized Trial of Recombinant Activated protein C (r-aPC) in the treatment of Thrombotic Microangiopathy.

5 Hemolytic-Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP) are two types of thrombotic microangiopathy that have endothelial damage as the inciting event. In these disease states, the endothelium is by either verotoxins from infectious organisms such as

10 E.coli O157:H7 and Shigella, drugs such as FK506 and ticlopidine, or autoantibodies. Endothelial damage leads to release of unusually large von Willebrand factor multimers, which in turn leads to platelet aggregation. Fibrin thrombi accumulate on the platelet thrombi as a result of depression

15 of the body's fibrinolytic system.

 In HUS and TTP, elevated levels of plasminogen activator inhibitor (PAI-1) and decreased levels of protein C activity have been found. The clinical findings of thrombotic microangiopathies include microangiopathic hemolytic anemia (MAHA), acute renal failure, thrombocytopenia, and in TTP, acute neurologic changes.

 The primary objective of this trial is to show that infusion of r-aPC leads to a statistically significant reduction in time to remission of the illness compared with

25 placebo. Secondary objectives are to show that infusion of r-aPC leads to statistically significant reductions in the number of days with renal failure, number of transfusions required, and number of convulsive episodes. The primary safety objective of this trial is to show that r-aPC does

30 not lead to a statistically significant increase in the

number of clinically significant bleeding events when compared to placebo.

Inclusion criteria for patients considered for entry into the trial is evidence of a thrombotic microangiopathy as defined by the presence of: 1) Thrombocytopenia defined as a platelet count $<80 \times 10^9$ cells/Liter; 2) Microangiopathic Hemolytic anemia (MAHA) defined as having >2 schistocytes per visual field on peripheral blood smear, a negative direct and indirect Coombs' test, and a Hgb of <10 g/dl; 3) acute renal insufficiency defined as a doubling in the patient's baseline serum creatinine or the presence of oliguria defined as a urine output <0.5 ml/kg/hr; and, 4) normal coagulation times (PT, PTT and fibrinogen). Patients are excluded from the trial if they are receiving an anticoagulant or an investigational agent. Patients with active bleeding from the respiratory or gastrointestinal tract are excluded from the study.

Patients who meet all inclusion criteria and no exclusion criteria are randomized to receive either placebo or a 96 hour infusion of r-aPC at a dose up to $48 \mu\text{g}/\text{kg}/\text{hr}$, which has previously been shown to raise the aPTT to 2X baseline. The following data is collected during the study: Hgb, platelet count, serum creatinine, 24 urine output, number of convulsive episodes, and the number of packed red blood cells transfused. The primary endpoint analyzed, i.e. time to remission of the illness, is defined by a persistent platelet count for 2 days in the absence of platelet transfusions of $>100 \times 10^9$ cells/Liter.

Therefore, therapy with r-aPC, with its anticoagulant and profibrinolytic activities along with its ability to

inactivate PAI-1, is useful for the treatment of the thrombotic microangiopathy that occur in patients with TTP and HUS.